NASDAQ:MEIP MEI Pharma (MEIP) Stock Price, News & Analysis → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free MEIP Stock Alerts $3.02 -0.05 (-1.63%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$3.01▼$3.0750-Day Range$3.01▼$4.2452-Week Range$2.99▼$7.97Volume8,473 shsAverage Volume12,707 shsMarket Capitalization$20.11 millionP/E Ratio0.77Dividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get MEI Pharma alerts: Email Address MEI Pharma MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside131.8% Upside$7.00 Price TargetShort InterestHealthy0.37% of Float Sold ShortDividend StrengthN/ASustainability-0.78Upright™ Environmental ScoreNews Sentiment0.73Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom $3.24 to ($4.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.29 out of 5 starsMedical Sector218th out of 921 stocksPharmaceutical Preparations Industry89th out of 428 stocks 3.0 Analyst's Opinion Consensus RatingMEI Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMEI Pharma has only been the subject of 1 research reports in the past 90 days.Read more about MEI Pharma's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.37% of the float of MEI Pharma has been sold short.Short Interest Ratio / Days to CoverMEI Pharma has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MEI Pharma has recently increased by 9.09%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMEI Pharma does not currently pay a dividend.Dividend GrowthMEI Pharma does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMEI Pharma has received a 71.00% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" product. See details.Environmental SustainabilityThe Environmental Impact score for MEI Pharma is -0.78. Previous Next 2.6 News and Social Media Coverage News SentimentMEI Pharma has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for MEI Pharma this week, compared to 1 article on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MEI Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.90% of the stock of MEI Pharma is held by insiders.Percentage Held by Institutions52.38% of the stock of MEI Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MEI Pharma's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for MEI Pharma are expected to decrease in the coming year, from $3.24 to ($4.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MEI Pharma is 0.77, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 128.53.Price to Earnings Ratio vs. SectorThe P/E ratio of MEI Pharma is 0.77, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 111.71.Price to Book Value per Share RatioMEI Pharma has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about MEI Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldThe 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. About MEI Pharma Stock (NASDAQ:MEIP)MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.Read More MEIP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MEIP Stock News HeadlinesMay 10, 2024 | investorplace.comMEIP Stock Earnings: MEI Pharma Beats EPS for Q3 2024May 9, 2024 | businesswire.comMEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational HighlightsMay 11, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.May 7, 2024 | americanbankingnews.comMEI Pharma (NASDAQ:MEIP) Stock Price Passes Below 200-Day Moving Average of $5.08May 7, 2024 | americanbankingnews.comMEI Pharma (NASDAQ:MEIP) Coverage Initiated at StockNews.comApril 18, 2024 | insidermonkey.com5 Cheap Penny Stocks to Buy According to AnalystsApril 11, 2024 | msn.comMEI Pharma shelves plans for a second return of capitalApril 11, 2024 | businesswire.comMEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344May 11, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.April 11, 2024 | businesswire.comMEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer PatientsApril 10, 2024 | businesswire.comMEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology ForumMarch 26, 2024 | finance.yahoo.comMEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid LeukemiaMarch 20, 2024 | stocknews.com3 Pharma Stocks Outperforming the CompetitionMarch 3, 2024 | investing.comMEI Pharma Inc (MEIP)February 29, 2024 | seekingalpha.comMEIP MEI Pharma, Inc.February 15, 2024 | businesswire.comGlancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)February 15, 2024 | businesswire.comGlancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)February 13, 2024 | finance.yahoo.comMEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational HighlightsFebruary 13, 2024 | finance.yahoo.comMEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue EstimatesFebruary 13, 2024 | businesswire.comMEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational HighlightsFebruary 8, 2024 | wsj.comMEI Pharma Inc.February 8, 2024 | finance.yahoo.comIs MEI Pharma (MEIP) Attractively Priced?January 18, 2024 | forbes.comAcceleron PharmaJanuary 16, 2024 | finance.yahoo.comMEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024December 27, 2023 | benzinga.comMEI Pharma Stock (NASDAQ:MEIP), Short Interest ReportDecember 27, 2023 | benzinga.comMEI Pharma Stock (NASDAQ:MEIP) Dividends: History, Yield and DatesDecember 11, 2023 | finance.yahoo.comMEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023See More Headlines Receive MEIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/13/2024Today5/11/2024Fiscal Year End6/30/2024Next Earnings (Estimated)9/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MEIP Previous SymbolNASDAQ:MSHL CUSIPN/A CIK1262104 Webwww.meipharma.com Phone(858) 369-7100Fax302-655-5049Employees46Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+132.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$2.97 Trailing P/E Ratio1.01 Forward P/E Ratio0.93 P/E GrowthN/ANet Income$-31,840,000.00 Net Margins39.06% Pretax Margin27.32% Return on Equity39.72% Return on Assets18.26% Debt Debt-to-Equity RatioN/A Current Ratio8.23 Quick Ratio8.23 Sales & Book Value Annual Sales$48.82 million Price / Sales0.41 Cash FlowN/A Price / Cash FlowN/A Book Value$3.70 per share Price / Book0.81Miscellaneous Outstanding Shares6,660,000Free Float6,403,000Market Cap$20.05 million OptionableOptionable Beta0.82 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. David M. Urso B.A. (Age 60)Esq., J.D., CEO, President & Director Comp: $748.46kDr. Richard G. Ghalie M.D. (Age 66)MBA, Chief Medical Officer Comp: $627.76kMr. Justin J. File (Age 54)CFO & Corporate Secretary Ms. Yomara Gomez-NaidenSenior Vice President of Operations & QualityMs. Nicole Chyoko IidaVice President of Legal AffairsMs. Anne FreseChief People OfficerDr. Robert D. Mass (Age 70)Strategic Advisor Comp: $201.68kMr. David A. Walsey J.D.L.L.M., Senior Vice President of Corporate AffairsMore ExecutivesKey CompetitorsAlaunos TherapeuticsNASDAQ:TCRTSol-Gel TechnologiesNASDAQ:SLGLBenitec BiopharmaNASDAQ:BNTCSynlogicNASDAQ:SYBXNanoViricidesNYSE:NNVCView All CompetitorsInsiders & InstitutionsAcadian Asset Management LLCSold 13,658 shares on 5/10/2024Ownership: 3.178%Cable Car Capital LLCBought 611,440 shares on 2/20/2024Ownership: 9.181%Anson Funds Management LpBought 48,060 shares on 9/22/2023Total: $329,211.00 ($6.85/share)Anson Funds Management LpBought 120,000 shares on 9/20/2023Total: $721,200.00 ($6.01/share)View All Insider TransactionsView All Institutional Transactions MEIP Stock Analysis - Frequently Asked Questions Should I buy or sell MEI Pharma stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MEIP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEIP, but not buy additional shares or sell existing shares. View MEIP analyst ratings or view top-rated stocks. What is MEI Pharma's stock price target for 2024? 1 brokers have issued twelve-month target prices for MEI Pharma's shares. Their MEIP share price targets range from $7.00 to $7.00. On average, they expect the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 131.8% from the stock's current price. View analysts price targets for MEIP or view top-rated stocks among Wall Street analysts. How have MEIP shares performed in 2024? MEI Pharma's stock was trading at $5.80 at the beginning of the year. Since then, MEIP shares have decreased by 47.9% and is now trading at $3.02. View the best growth stocks for 2024 here. When is MEI Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, September 24th 2024. View our MEIP earnings forecast. How were MEI Pharma's earnings last quarter? MEI Pharma, Inc. (NASDAQ:MEIP) released its quarterly earnings results on Tuesday, February, 13th. The company reported ($1.66) earnings per share for the quarter, missing analysts' consensus estimates of ($1.46) by $0.20. MEI Pharma had a trailing twelve-month return on equity of 47.42% and a net margin of 39.06%. How often does MEI Pharma pay dividends? What is the dividend yield for MEI Pharma? MEI Pharma declared a dividend on Monday, November 6th. Stockholders of record on Friday, November 17th will be given a dividend of $1.75 per share on Wednesday, December 6th. The ex-dividend date of this dividend is Thursday, November 16th. Read our dividend analysis for MEIP. When did MEI Pharma's stock split? MEI Pharma shares reverse split on the morning of Monday, April 17th 2023. The 1-20 reverse split was announced on Monday, April 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of MEI Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other MEI Pharma investors own include Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), OPKO Health (OPK), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE) and TherapeuticsMD (TXMD). Who are MEI Pharma's major shareholders? MEI Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Acadian Asset Management LLC (3.18%). Insiders that own company stock include Anson Funds Management Lp and Charles V Baltic III. View institutional ownership trends. How do I buy shares of MEI Pharma? Shares of MEIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MEIP) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHow Biden has already won 2024Porter & CompanyRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable ProsperityForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MEI Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.